The genes encoding the histone acetyl-transferases (HATs) CREB binding protein (CREBBP) and EP300 are recurrently mutated in the activated B cell-like and germinal center (GC) B cell-like subtypes of diffuse large B cell lymphoma (DLBCL). Here, we introduced a patient mutation into a human DLBCL cell line using CRISPR and deleted Crebbp and Ep300 in the GC B cell compartment of mice. CREBBPmutant DLBCL clones exhibited reduced histone H3 acetylation, expressed significantly less MHCII, and grew faster than wild-type clones in s.c. and orthotopic xenograft models. Mice lacking Crebbp in GC B cells exhibited hyperproliferation of their GC compartment upon immunization, had reduced MHCII surface expression on GC cells, and developed accelerated MYC-driven lymphomas. Ep300 inactivation reproduced some, but not all, consequences of Crebbp inactivation. MHCII deficiency phenocopied the effects of CREBBP loss in spontaneous and serial transplantation models of MYC-driven lymphomagenesis, supporting the idea that the mutational inactivation of CREBBP promotes immune evasion. Indeed, the depletion of CD4 + T cells greatly facilitated the engraftment of lymphoma cells in serial transplantation models. In summary, we provide evidence that both HATs are bona fide tumor suppressors that control MHCII expression and promote tumor immune control; mutational inactivation of CREBBP, but not of EP300, has additional cell-intrinsic engraftment and growth-promoting effects.
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epigenetic modifiers | DLBCL pathogenesis | xenotransplantation models | tumor suppressor P erturbations of the epigenome due to mutations occurring in histone-modifying enzymes are emerging as a driving force in the pathogenesis of diffuse large B cell lymphoma (DLBCL) (1) . The two main cell-of-origin subtypes of DLBCL, the activated B cell (ABC) and germinal center (GC) B cell-like (GCB) subtype, are both commonly affected by mutations in epigenetic modifiers (2) . The most common recurrent somatic mutations in histonemodifying enzymes are loss-of-function mutations of the histone methyltransferase (HMT) KMT2D (also known as MLL2), gainof-function mutations of the HMT EZH2, and loss-of-function mutations of the histone acetyltransferases CREB binding protein (CREBBP) and EP300. Together, these somatic mutations occur in ∼50% of DLBCL patients (2) , and are believed to be founder events that predispose normal B cells to malignant transformation (1) . DLBCL is characterized by extraordinary genetic diversity, both within and across tumors, which has been linked largely to the activity of activation-induced cytidine deaminase (AID), the enzyme responsible for introducing mutations in the Ig locus and, thereby, enabling the formation of high-affinity antibodies, and its effects on nonimmunoglobulin genes (3). More recently however, epigenetic heterogeneity has emerged as an equally important hallmark of DLBCL, with strong evidence for diversity in both DNA modifications (especially cytosine methylation) and the posttranslational modifications of histones. A higher degree of intertumoral and intratumoral heterogeneity has been associated directly with disease aggressiveness, likelihood of relapse, and inferior patient survival (4) (5) (6) .
The contribution of mutations in histone-modifying enzymes to DLBCL initiation and progression is subject to intense investigation. Loss-of-function mutations in KMT2D disrupt histone H3 lysine K4 (H3K4) monomethylation and dimethylation and mostly affect gene enhancer regions, promoting the proliferation of GC B cells and preventing their terminal differentiation (7) . KMT2D mutations occur in 23-32% of DLBCL patients (2, 8) and are even more common in follicular lymphoma (FL); in animal models, KMT2D loss synergizes with BCL2 to accelerate lymphomagenesis (7) . Lymphomas from patients with gain-of-function EZH2 mutations show aberrant repression of GC-specific proliferation checkpoint genes, and mice engineered to express mutant EZH2 exhibit a massive expansion of GC B cells due to aberrant proliferation and differentiation blockade (9) . Mutations in CREBBP and EP300 affect more than 30% of DLBCL and FL patients, and usually remove or inactivate the histone acetyl-transferase (HAT) coding domain of either gene (10) ; CREBBP in particular has been shown to function as part of an enhancer/superenhancer network that regulates GC/post-GC cell fate decisions, plasma cell differentiation,
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Genes encoding chromatin-modifying enzymes such as the histone acetyl-transferases (HATs) are often mutated in diffuse large B cell lymphoma (DLBCL), the most common lymphoma of adults. Here, we shed light on the tumor suppressive activity of HATs in human diffuse large B cell lymphoma (DLBCL) cell lines and in mice. Cell lines harboring an experimentally introduced patient mutation in the HAT CREBBP lose their MHCII expression and form tumors faster in subcutaneous and orthotopic xenograft models. Mice that lack Crebbp specifically in the germinal center B cell compartment also lose their MHCII expression in that compartment, and show hyperproliferation of germinal center B cells upon immunization, which predisposes them to MYC-driven lymphomagenesis. Our data implicate HATs as tumor suppressors in DLBCL.
and antigen presentation by opposing the suppressive activities of BCL6/SMRT/HDAC3 complexes (11, 12) .
Here, we have investigated the mutational status of CREBBP and EP300 in a panel of 11 DLBCL cell lines relative to their H3 acetylation. CRISPR technology was used to edit the CREBBP locus in a wild-type cell line, and CREBBP-mutant and wild-type DLBCL clones were subjected to xenotransplantation studies in s.c. and orthotopic models. We further generated mice with a Crebbp deletion specifically in the GC B cell compartment and assessed the contribution of Crebbp or MHCII loss, and CD4 + T cell depletion, to lymphomagenesis in spontaneous and serial transplantation models driven by the overexpression of MYC. All available evidence from the various models implicates the HATs as important tumor suppressors in DLBCL pathogenesis.
Results
The CREBBP and EP300 Genomic Loci Are Recurrently Mutated in DLBCL Cell Lines, Which Affects Histone H3 Acetylation and HLA Expression. To determine the mutational status of a panel of 11 DLBCL cell lines, we performed targeted resequencing of the 31 exons each of the CREBBP and EP300 genomic loci (Fig. 1A) . Only 2 of the 11 cell lines, U-2932 and OCI-Ly3, were found to be wild type for both alleles each of CREBBP and EP300, indicating that mutations targeting these loci were even more common in our panel of cell lines (>80%; Fig. 1A ) than in previously examined DLBCL patient cohorts (2, 10) . The two CREBBP/ EP300-wild-type cell lines U-2932 and OCI-Ly3 expressed clearly detectable amounts of full-length CREBBP and EP300 (Fig. 1B) . Of the remaining nine cell lines, three exhibited monoallelic or biallelic mutations or deletions of EP300, leading to the partial (SU-DHL-10) and complete (SU-DHL-2, RC-K8) loss, respectively, of EP300 expression (Fig. 1B) . The acetylation of H3 on residues K18 and 27, and to some extent on K14, was reduced in the three EP300-mutant cell lines relative to the two wild-type cell lines (Fig. 1B) , whereas the acetylation level of K9 did not mirror the other three residues (Fig. S1A) . The remaining six DLBCL cell lines exhibited evidence of monoallelic (5/6) or biallelic (1/6) mutational inactivation of CREBBP by either truncating mutations leading to immature stop codons, or amino acid substitutions or chromosomal translocations that detectably affect CREBBP expression levels ( Fig. 1 A and B) . Reduced or prematurely truncated CREBBP expression coincided with strongly reduced H3K14, H3K18, and H3K27 acetylation in all CREBBP-mutant cell lines (Fig. 1B) , with the notable exception of SU-DHL-6, which maintains high-level CREBBP expression due to a trisomy of chromosome 16. Interestingly, mutations in CREBBP and EP300 were mutually exclusive in our cell line panel as had been shown in primary DLBCL samples (2, 10) , and the loss of just one of the total of four CREBBP/EP300 alleles was sufficient to produce a clear phenotype in terms of H3K14, H3K18, and H3K27 acetylation ( Fig. 1 A and B) . In contrast, the acetylation of P53, which has been attributed to HATs and their putative activity on nonhistone targets (10), was not affected by single-copy losses of CREBBP or EP300 (Fig. S1B) . ABC-and GCB-DLBCL-derived cell lines were equally affected by CREBBP/EP300 mutational inactivation.
To assess in a more controlled setting whether CREBBP and EP300 expression affects H3 acetylation and histone modificationdependent target gene expression, we used RNA interference to silence both HATs in the wild-type cell line U-2932. The specific depletion of CREBBP or EP300, or of both HATs combined, reduced H3K14, K18, and K27 acetylation ( Fig. 1C and Fig. S1 C-F). A genomic locus that is believed to be regulated by histone acetylation in B cells, especially on residues modified by CREBBP/ EP300, is the HLA locus. Chromatin immunoprecipitation using H3K18-acetyl-specific and H3K27-acetyl-specific antibodies followed by qPCR confirmed that the CREBBP/EP300-wild-type cell line U-2932 indeed exhibits strong acetylation of K18 and K27 at regulatory elements upstream of the HLA-DRA transcription start site, but not at downstream regions of the gene or the MyoD control gene (Fig. 1D ). The loss of CREBBP and EP300 expression significantly reduced HLA transcript levels, but did not affect an irrelevant control gene (Fig. 1E) . The combined results indicate that the CREBBP and EP300 genomic loci are recurrently mutated in both ABC-and GCB-DLBCL cell lines, and that their gene products contribute to histone H3 acetylation and promote active transcription in DLBCL cells at a locus known to be specifically regulated by this epigenetic mechanism.
Genome Editing of CREBBP Mimicking a Patient Mutation Reduces Histone Acetylation and HLA Expression, but Does Not Affect in Vitro Growth Kinetics. We next devised a strategy that allowed us to mutate one allele of the CREBBP locus in the wild-type U-2932 cell line and to thereby mimic a previously identified patient mutation, at position A4171T, leading to a premature truncation of CREBBP at amino acid K1323X and the loss of a functional (C) U-2932 cells were treated with control siRNA or siRNAs specific for CREBBP, EP300, or both (pool); protein lysates were harvested after 72 and 96 h and subjected to immunoblot analysis using the indicated antibodies. A representative experiment is shown along with the densitometric quantification of four independent experiments. (D) Profile of histone acetylation at the HLA-DRA locus. ChIP of U-2932 cells was performed with H3K18ac, H3K27ac and control IgG antibody and was followed by PCRs of the eight regions indicated on the x axis. (E) Relative expression of HLA-DRA and HLA-DRB1 and of WEE1 as control, normalized to RPLP32, as assessed by qRT-PCR of U-2932 cells treated with siRNAs for 48 h as described in C. Data in C and E represent means + SD of four biological replicates. **P < 0.01; ***P < 0.001; ****P < 0.0001. n.d., not detectable.
HAT domain. We aimed to mutate only one allele because most patient mutations in CREBBP and EP300 are monoallelic. Genome editing was accomplished by CRISPR technology using guide RNAs that were designed to promote the excision of exon 23, one of 12 exons encoding the HAT domain of CREBBP (Fig. S2A) . In 5 of >100 examined clones, the excision event had resulted in a frame shift leading to a premature (monoallelic) truncation of CREBBP. The resulting protein lacks the C terminus and more than half of the HAT domain ( Fig. 2A and Fig. S2B ). Whereas control, unedited clones expressed copious amounts of full-length CREBBP, the mutant clones exhibited a clear reduction of fulllength CREBBP and instead featured an extra band representing the truncated protein ( Fig. 2A) . The expression of EP300 was not affected by genomic editing of the CREBBP locus, with the exception of one clone ( Fig. 2A) . As expected, H3 acetylation was reduced in the clones expressing full-length CREBBP from only one allele relative to the wild-type clones ( Fig. 2A) . Transcriptional profiling of five mutant and five wild-type clones by RNA sequencing revealed more than 100 strongly differentially regulated genes due to partial loss of CREBBP activity (Fig. 2B and Dataset S1, GEO accession no. GSE89879). The dominant biological process as determined by gene ontology analysis was "antigen processing and presentation," as numerous MHCII genes, and the master regulator of MHCII expression, CIITA, were among the most differentially regulated genes (Fig. 2B) . Loss of MHCII expression due to CREBBP loss was confirmed by qRT-PCR for HLA-DRA and HLA-DRB1 transcripts (Fig. 2C) , confirming the results obtained by siRNA-mediated knock-down of CREBBP and EP300. Other interesting CREBBP target genes (down-regulated in mutant clones) include CREBBP itself and the surface receptors CD19, CD74, S1PR1, IFNAR2, and CD52. Surprisingly, almost half of dysregulated genes were up-regulated in the mutant clones despite the fact that CREBBP adds active (rather than repressive) histone marks (Fig. 2B and Dataset S1). We next examined the growth properties of the 10 clones under various culture conditions in vitro; all clones grew equally fast in standard cell culture media, irrespective of their CREBBP status (Fig. S2 C and D) , and even under exposure to the histone deacetylase (HDAC) inhibitors sodium 4-phenylbutuyrate (PBA) or valproic acid sodium salt (VPA) (Fig. S2 E and F) . Similarly, we could not detect differential susceptibility to HDAC inhibitors of our CREBBP/EP300 wild-type and mutant cell lines (Fig. S2 G and H) . The combined results indicate that HAT inactivation has profound effects on global histone H3 acetylation and affects the expression of numerous genes, most notably MHCII genes, but does not confer obvious growth advantages in in vitro culture systems.
Monoallelic CREBBP Inactivation Promotes s.c. and Orthotopic Growth of Xenografted DLBCL Cell Lines in Immunocompromised Mice. We next s.c. transplanted a subset of CREBBP-mutant and wild-type clones onto the flanks of nod/scid/common gamma chain knockout (NSG) mice, and determined the tumor growth over time and at the study end point. CREBBP-mutant clones grew faster, and had reached a larger tumor weight and volume at the study endpoint than wild-type clones (Fig. 3A and Fig. S3A ). The same effect was observed in a mouse strain expressing various human cytokines that have been knocked into the respective Pooled data from two studies are shown in C, and data from one of the two studies is shown in D. P values were calculated using the Mann-Whitney test. *P < 0.05; **P < 0.01; ****P < 0.0001. (Fig. S3C) , indicating that CREBBP loss may confer a growth advantage in this orthotopic but passage-dependent model. Most notably, however, we observed that both CREBBP-wild-type and -mutant clones engrafted in the bone marrow of MISTRG mice even without prior passaging (Fig. 3C) , with involvement of the kidneys and ovaries observed in some, but not all mice (Fig. S3D) ; involvement of other lymphoid organs such as the spleen was not observed with U2932 cells. CREBBP +/− clones engrafted more readily than CREBBP +/+ clones in the bone marrow of MISTRG mice (Fig.  3C) , suggesting that the loss of CREBBP confers a growth advantage in this orthotopic model. Interestingly, CREBBP-mutant clones exhibited lower HLA-DR expression even after extended growth in vivo (Fig. 3D) . hCD20 was stained for comparison, and did not differ among mutant and wild-type clones (Fig. 3D) . The combined results suggest that CREBBP inactivation confers a growth advantage in vivo despite comparable in vitro growth rates, and introduce a model of DLBCL xenotransplantation that supports orthotopic growth without prior conditioning of human lymphoma cells.
GC B Cell Hyperproliferation and Loss of MHCII Expression upon
Deletion of Crebbp. We next sought to establish a mouse model that would allow the specific monoallelic and biallelic deletion of Crebbp and Ep300 in the GC B cell compartment. To this end, we crossed mice expressing Cre recombinase under the activationinduced cytidine deaminase promoter (AID-Cre) with mice harboring floxed Crebbp or Ep300 alleles. The composite strains were immunized i.p. with sheep red blood cells (SRBCs) to induce AIDCre activity and GC formation. The expected excision of floxed alleles due to AID-Cre activity in the GC compartment was verified by the parallel immunization of AID-Cre × loxP-stop-loxP-RFP reporter mice (Fig. S4 A and B) . Five consecutive rounds of SRBC immunization induced GC formation in the spleen and an increase in CD19
low GC B cells (Fig. 4 A and B) . Interestingly, the deletion of one or both alleles of Crebbp led to hyperproliferation of the GC compartment relative to Crebbp-proficient animals; this effect was observed for all GC B cells (Fig. 4 A and B) , irrespective of which of three alternative gating strategies was used to identify them (Fig. S4C) , as well as for centroblasts and centrocytes that were differentiated based on their CD86 and CXCR4 expression ( Fig. 4B and Fig. S4 C and D) . The plasmablast and plasmacyte pools increased due to immunization but were not visibly affected by loss of Crebbp (Fig. S4 E and F) . Strikingly, quite the opposite effects were observed upon deletion of one or both alleles of Ep300: Ep300-deficient mice generated lower numbers of GC B cells, centroblasts, and centrocytes upon immunization (Fig. 4 A and B and Fig. S4D) . To obtain additional complementary information on the GC compartment of the same mice, we stained spleen sections cut at various depths for Ki67 and quantified GC numbers and size; this approach revealed that the size of individual GCs, but not their multiplicity, accounts for the increase in GC B cells in Crebbp-mutant mice, and the decrease in Ep300-mutant mice (Fig. 4C and Fig. S4G) .
GC B cells lacking one or both alleles of either Ep300 or Crebbp further exhibited reduced MHCII expression relative to Crebbp/Ep300-proficient GC B cells; this was true for all GC B cells, and especially for centroblasts (Fig. 4 D and E and Fig.  S4H ). The loss of Ep300 mirrored the effects of Crebbp loss on MHCII expression (Fig. 4 D and E and Fig. S4H ). Finally, to examine whether the loss of Crebbp would promote MYC-driven lymphomagenesis, we crossed AID-Cre × Crebbp fl/wt mice with a mouse strain that expresses MYC under the control of the Ig heavy chain enhancer (Emu-MYC) (15) . Interestingly, the loss of one Crebbp allele was sufficient to significantly accelerate the formation of MYC-driven nodal B cell lymphomas but was not sufficient to induce lymphomas in the absence of this second hit Crebbp wt/wt MYC-expressing lymphoma cells, respectively, that were harvested from the pooled inguinal and axillary lymph nodes of lymphoma-bearing donors. Mice were assessed with respect to their lymph node weights (inguinal and axillary LNs are plotted separately for each recipient and share the same color code) and lymph node B cell MHCII expression at the study endpoint (28 d after transplantation), relative to two nontransplanted controls. P values were calculated using the Mann-Whitney test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (Fig. 4F) ; furthermore, we found that upon i.v. transplantation of equal numbers of tumor cells from Crebbp-proficient or Crebbpdeficient lymphoma-bearing donors, the latter cells engrafted more readily in the lymph nodes and spleens of wild-type recipient mice, and retained their low MHCII expression relative to Crebbpproficient cells (Fig. 4G and Fig. S4I ). We conclude from the combined results that HATs control MHCII expression in both human and murine B cells and that the loss of Crebbp, but not of Ep300, additionally contributes to the immunization-induced expansion of the GC compartment; both phenomena appear to predispose to malignant transformation.
The Loss of MHCII Expression, or CD4
+ T-Cell Depletion, Promotes MYC-Driven Lymphomagenesis. To address whether the loss of MHCII expression that results from HAT inactivation promotes lymphomagenesis, we crossed mice lacking MHCII with Emu-MYC mice. MHCII −/− mice developed MYC-driven tumors earlier than their MHCII +/+ littermates; however, the fraction of mice that did not develop lymphomas at all in the time frame of observation (80 d) was comparable in the two groups (Fig. 5A) . MHCII −/− mice lack MHCII-restricted CD4 + T cells in all lymphoid tissues (Fig. S5A) , which might explain their enhanced predisposition to MYC-driven lymphomagenesis. To dissect whether the loss of MHCII affects lymphomagenesis in immunocompetent mice with normal CD4
+ T cell frequencies, we transplanted 100,000 MHCII −/− or MHCII +/+ MYC-expressing tumor cells pooled from the axillary and inguinal lymph nodes of two donors per genotype into wild-type C57BL6 recipients and recorded the tumor incidence. Whereas only 2 of 16 recipients of MHCII +/+ cells developed lymphomas with this low dose of cells, 10 of 17 recipients of MHCII −/− cells did (Fig. 5B) . The differential engraftment of MHCII-proficient and MHCII-deficient cells was reflected in on average significantly higher spleen and lymph node weights of recipients of MHCII −/− cells, and more efficient engraftment of tumor cells in bone marrow (Fig. 5C) . Finally, to confirm that MHCII-restricted T cells indeed control lymphomagenesis in the serial transplantation model, we depleted CD4 + T cells starting at either 1 d before injection of a saturating dose of 1 million tumor cells, or once palpable tumors had formed in the inguinal and axillary lymph nodes on day 11 after transplantation. The depletion of CD4 + T cells was efficient in all examined organs (Fig. S5B) and strongly enhanced lymphoma cell engraftment and growth in lymph nodes, spleen, and bone marrow, especially if T cells were depleted from the start of the experiment (Fig. 5D) . The combined results are consistent with the notion that the loss of MHCII expression confers a tumor cell survival benefit, especially during lymphoma initiation, indicating that immune surveillance driven by CD4 + T cells limits lymphomagenesis in immunocompetent animals.
Discussion
In this study, we have combined targeted resequencing of the genes encoding the HATs CREBBP and EP300 with experimental approaches using cell cultures and mouse models to shed light on the potential tumor suppressive activity of HATs in DLBCL. As expected from previous studies using patient cohorts (2, 8, 10) , our panel of 11 DLBCL cell lines confirmed that inactivating mutations in CREBBP and EP300 are common, monoallelic, and mutually exclusive and typically compromise the enzymatic activity of both enzymes, leading to strongly reduced levels of histone H3 acetylation of the lysine residues K14, K18, and K27. The siRNA-mediated knockdown of CREBBP, alone and especially in combination with EP300, strongly reduced global H3 acetylation at the same three residues, but did not affect the acetylation of nonhistone proteins.
To model HAT function in DLBCL cell lines in a manner that would recapitulate the dosage effect of monoallelic mutational CREBBP inactivation and a possible dominant negative effect of truncated protein resulting from the introduction of premature stop codons, we introduced a typical patient mutation monoallelically into a CREBBP/EP300-wild-type cell line. The expression of truncated CREBBP resulted in reduced global H3K18 acetylation and large changes in gene expression. The dominant category of dysregulated genes contained the various alleles of MHCII genes involved in antigen presentation, as well as their master regulator, the transcription factor CIITA, which could be confirmed not only by targeted qRT-PCR in the human DLBCL cell line clones, but also in murine GC B cells upon Cre-mediated excision of Crebbp or Ep300. The dependence of MHCII expression on active histone marks added by HATs thus appears to be a universal feature of murine and human B cells, which could further be confirmed experimentally by chromatin immunoprecipitation of the HLA-DRA locus with acetyl-H3-specific antibodies. The transcriptional signature we identified here to be linked to CREBBP-mediated histone modification is consistent with previous reports showing that CREBBP regulates superenhancer networks with central roles in GC/post-GC cell fate decisions, including genes involved in signal transduction by the B cell receptor and CD40 receptor, assessed with respect to spleen and LN weights (one data point per mouse, the mean of two inguinal and axillary LNs is shown) and B cell frequencies in bone marrow at the study endpoint (28 d after transplantation), relative to five nontransplanted controls. Mice were additionally treated weekly with CD4-specific or isotype control antibody, starting either at 1 d before transplantation, or once palpable tumors had formed (at 11 d after transplantation). Pooled data from two studies are shown in D. P values were calculated using the Mann-Whitney test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
transcriptional control of GC and plasma cell development, and antigen presentation (11, 12) . The reduced expression of MHCII is an obvious, but not the only, consequence of HAT inactivation in CREBBP-mutant DLBCL cell lines. Mutant clones grow faster when s.c. transplanted into NSG mice, and CREBBP-mutant tumors are larger and heavier at the study endpoint than wild-type tumors. The same was true in Rag2 −/− γc −/− mice that express several human cytokines, allowing for efficient engraftment of various human immune cell compartments (13) . The differential growth in both xenograft models is unlikely to be due to immune evasion caused by MHCII down-regulation, a mechanism that has been proposed to explain the lack of T cell activation and proliferation in CREBBP-mutant FL (16) . In FL, CREBBP mutations are known to occur within the earliest inferable progenitor, result in decreased MHCII expression on tumor B cells, and correlate with decreased frequencies of tumor-infiltrating CD4 + helper T cells (16) . As antitumor immunity driven by CD4 + T cells can be ruled out in the two immunocompromised xenograft models used here, CREEBP-mutant tumors must benefit from additional cellintrinsic growth advantages conferred by loss of HAT activity in this setting. The same was observed in genetically manipulated mice, where the loss of one or both alleles of Crebbp led to hyperproliferation of the GC B cell compartment upon immunization. The dysregulated expansion of the GC compartment likely provides a setting in which additional mutations can accumulate and early clonal lesions can arise, especially given the genomic instability that is an inherent feature of GC B cells; indeed, Crebbp loss accelerated MYC-driven lymphomagenesis in both spontaneous and serial transplantation models. We hypothesize that CREBBP mutations confer two distinct benefits during DLBCL pathogenesis, one promoting unrestricted growth during the GC reaction, and the other promoting immune evasion. Our results showing enhanced engraftment of MHCIInegative, MYC-expressing lymphoma cells into immunocompetent mice provide experimental evidence for the concept that the loss of MHCII expression indeed promotes immune evasion in this setting. This result was phenocopied by CD4 + T cell depletion, indicating that MHCII-restricted T cells control early events of lymphomagenesis in immunocompetent hosts, either through direct cytotoxic effects on tumor B cells or by creating a cytokine milieu that is not conducive to tumor initiation and/or progression. Interestingly, only one of the two biological functions of CREBBP appears to be shared by EP300. Ep300 inactivation in the mouse GC compartment down-regulates MHCII expression to an extent that is comparable to Crebbp inactivation; in contrast, the hyperproliferation of the GC compartment upon immunization was not seen in Ep300 mutant mice, which rather exhibited a contraction of their GC B cells. Thus, EP300 and CREBBP have both shared and distinct activities, which, in turn, is reflected by the much more common mutational inactivation of CREBBP than of EP300 in DLBCL patients (2, 8, 10) .
In addition to their role as bona fide tumor suppressors in DLBCL and mechanistic contribution to the control of the GC reaction and antigen presentation, wild-type HAT activity also confers clear and previously unknown benefits in terms of patient survival (17) . Furthermore, HAT mutational inactivation likely predicts treatment responses to targeted therapies with epigenetically acting drugs, such as the HDAC3 inhibitors (11, 18) . In summary, our results provide evidence for two complementary tumor suppressive mechanisms in GC B cells that depend on HAT enzymes, of which one controls proliferation in a cellautonomous manner, and the other sensitizes malignant B cells to CD4
+ T cell-mediated tumor control. 
